Pharma & Biotech
BioNTech at a Crossroads: FDA Filing Looms as Phase 3 Pipeline Takes Shape
The shares trade at €77 — roughly 27% below the 52-week high and below both their 50-day and 200-day moving...
Ocugen’s Mutation-Agnostic Gene Therapy Edges Toward FDA Filing as $130M Financing Secures Runway to 2028
Ocugen is betting that a single therapeutic can rewrite the rules for treating inherited retinal diseases. Its lead candidate, OCU400,...
Bayer’s Slow Build: Clinical Evidence and Margin Pressures Define the Next Chapter
Bayer is attempting to write a new chapter, one built on clinical proof rather than corporate promises. The German conglomerate's...
BioNTech’s Oncology Data Wows, but the Stock Won’t Budge: A $1 Billion Buyback Meets Investor Skepticism
The numbers from Chicago were impressive. On May 30, BioNTech and Bristol Myers Squibb unveiled interim Phase 2 results for...
Novo Nordisk’s 15 Billion Kroner Buyback Sends a Message, but the Market Isn’t Listening
The Danish drugmaker is buying back its own stock at a furious pace just as the shares slide toward a...
Bayer’s Summer of Reckoning: Legal Decisions and a Potential Blockbuster Collide
Bayer’s stock is caught in a familiar squeeze: strong operational performance and promising drug data are consistently overshadowed by the...
Newron’s Steep Descent Accelerates as Evenamide Hopes Hinge on Conference Circuit
The sell-off in Newron Pharmaceuticals has shown no signs of letting up. Shares closed last Friday at €13.15, marking a...
Bayer’s Fundamentals Swing Upward, but the 200-Day Line Remains a Battleground
Bayer delivered a first-quarter earnings report that should have been a catalyst for its stock. Adjusted earnings per share jumped...
BioNTech’s Bet on BNT323 Intensifies as Restructuring and Pipeline Data Pave Way for Regulatory Milestone
The next few months will decide whether BioNTech can turn its sprawling oncology pipeline into a revenue-generating reality. With a...
Ocugen’s Data-Driven Countdown: Three Parallel Catalysts Converge in Q3 2026
Ocugen’s stock has been on a rollercoaster, sliding 25% over the past month to trade at €1.18, but the company...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
